# SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

> **NCT05935384** · — · RECRUITING · sponsor: **Guardant Health, Inc.** · enrollment: 470 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- Colorectal Cancer
- Breast Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Guardant360

## Key facts

- **NCT ID:** NCT05935384
- **Lead sponsor:** Guardant Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-25
- **Primary completion:** 2030-12-30
- **Final completion:** 2030-12-30
- **Target enrollment:** 470 (ESTIMATED)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05935384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05935384, "SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05935384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*